Treats partial-onset or primary generalized tonic-clonic seizures. ANDA 205976, held by Ph Health. Topiramate.
As of Nov 15, 2026, ANDA 205976 (Topiramate), held by Ph Health, was first approved by FDA on May 4, 2023, with 0 approved supplements and 0 published complete response letters.
Topiramate extended-release capsules are indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older; adjunctive therapy for the treatment of partial-onset, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome (LGS) in patients 6 years of age and older Preventive treatment of migraine in patients 12 years of age and older 1.1 Monotherapy Epilepsy Topiramate extended-release capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older. 1.
| May 4, 2023 | Original application | Approved | None posted |
| Mar 1, 2023 | Original application | Approved | None posted |
| Topiramate200MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate25MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate50MG · capsule, extended release;oral | Topiramate | Rx |
| Topiramate100MG · capsule, extended release;oral | Topiramate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters